Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | Unknown unknown |
Therapy | Sotrastaurin |
Indication/Tumor Type | uveal melanoma |
Response Type | not applicable |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | uveal melanoma | not applicable | Sotrastaurin | Phase I | Actionable | In a Phase I trial, AEB071 treatment was safe and tolerable in patients with uveal melanoma and led to a partial response in 3% (4/153), stable disease in 50% (76/153) with a median duration of 15 weeks, and a median progression-free survival of 3.5 months (PMID: 32029634; NCT01430416). | 32029634 |
PubMed Id | Reference Title | Details |
---|---|---|
(32029634) | Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071. | Full reference... |